AR122018A1 - Proteínas que se unen a nkg2d, cd16 y clec12a - Google Patents

Proteínas que se unen a nkg2d, cd16 y clec12a

Info

Publication number
AR122018A1
AR122018A1 ARP210101229A ARP210101229A AR122018A1 AR 122018 A1 AR122018 A1 AR 122018A1 AR P210101229 A ARP210101229 A AR P210101229A AR P210101229 A ARP210101229 A AR P210101229A AR 122018 A1 AR122018 A1 AR 122018A1
Authority
AR
Argentina
Prior art keywords
binding proteins
nkg2d
clec12a
clec12a binding
multispecific binding
Prior art date
Application number
ARP210101229A
Other languages
English (en)
Inventor
Hemanta Baruah
Gregory P Chang
Ann F Cheung
Daniel Fallon
Asya Grinberg
Zong Sean Juo
Christopher Ryan Morgan
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of AR122018A1 publication Critical patent/AR122018A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Aquí se describen proteínas de unión multiespecíficas que se unen al receptor NKG2D, CD16 y CLEC12A, composiciones farmacéuticas que comprenden las proteínas de unión multiespecíficas, y métodos terapéuticos útiles para el tratamiento del cáncer.
ARP210101229A 2020-05-06 2021-05-05 Proteínas que se unen a nkg2d, cd16 y clec12a AR122018A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063020798P 2020-05-06 2020-05-06

Publications (1)

Publication Number Publication Date
AR122018A1 true AR122018A1 (es) 2022-08-03

Family

ID=78468474

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101229A AR122018A1 (es) 2020-05-06 2021-05-05 Proteínas que se unen a nkg2d, cd16 y clec12a

Country Status (15)

Country Link
US (1) US20220119534A1 (es)
EP (1) EP4146271A1 (es)
JP (1) JP2023508942A (es)
KR (1) KR20230008181A (es)
CN (1) CN115836088A (es)
AR (1) AR122018A1 (es)
AU (1) AU2021268340A1 (es)
BR (1) BR112022021884A2 (es)
CA (1) CA3177024A1 (es)
CL (1) CL2022003077A1 (es)
CO (1) CO2022015929A2 (es)
IL (1) IL297922A (es)
MX (1) MX2022013944A (es)
TW (1) TW202208428A (es)
WO (1) WO2021226193A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170022291A1 (en) * 2014-04-01 2017-01-26 Adimab, Llc Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
CA3054079A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
US20210101976A1 (en) * 2018-02-20 2021-04-08 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2023107956A1 (en) * 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023201238A1 (en) * 2022-04-11 2023-10-19 Vor Biopharma Inc. Binding agents and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
WO2017079834A1 (en) * 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta and conformationally-selective antibodies thereto
US20210198368A1 (en) * 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
CN110267678A (zh) * 2016-10-29 2019-09-20 霍夫曼-拉罗奇有限公司 抗mic抗体和使用方法
CN113004391A (zh) * 2017-08-16 2021-06-22 蜻蜓疗法股份有限公司 结合nkg2d、cd16和egfr、ccr4或pd-l1的蛋白质
CN111432832A (zh) * 2017-09-14 2020-07-17 蜻蜓疗法股份有限公司 结合nkg2d、cd16和c-型凝集素样分子-1(cll-1)的蛋白质
MX2020008683A (es) * 2018-02-20 2020-12-07 Dragonfly Therapeutics Inc Dominios variables de anticuerpo que se dirigen a cd33 y sus usos.
CA3113539A1 (en) * 2018-10-10 2020-04-16 Zymeworks Inc. Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof

Also Published As

Publication number Publication date
CA3177024A1 (en) 2021-11-11
CO2022015929A2 (es) 2023-02-16
BR112022021884A2 (pt) 2022-12-20
IL297922A (en) 2023-01-01
CN115836088A (zh) 2023-03-21
MX2022013944A (es) 2022-11-30
AU2021268340A1 (en) 2022-12-08
TW202208428A (zh) 2022-03-01
CL2022003077A1 (es) 2023-07-21
WO2021226193A1 (en) 2021-11-11
EP4146271A1 (en) 2023-03-15
JP2023508942A (ja) 2023-03-06
KR20230008181A (ko) 2023-01-13
US20220119534A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
AR122018A1 (es) Proteínas que se unen a nkg2d, cd16 y clec12a
CO2022004757A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
CY1125025T1 (el) 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
CL2020002036A1 (es) Terapia de combinación del cáncer que incluye proteínas de unión multiespecíficas que activan a las células asesinas naturales
CO2021013279A2 (es) Anticuerpos de cadena pesada que se unen al psma
MX2019009848A (es) Proteínas que se unen a her2, nkg2d y cd16.
MX2019009566A (es) Proteinas de union a bcma, nkg2d y cd16.
CL2021000316A1 (es) Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso
CO2022017348A2 (es) Anticuerpos anti-tigit
MX2019009541A (es) Proteinas que se unen a psma, nkg2d y cd16.
CO2022003703A2 (es) Conjugados terapéuticos
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
MX2019009847A (es) Proteínas que se unen a cd123, nkg2d y cd16.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
BR112023002116A2 (pt) Proteínas que se ligam a nkg2d, cd16 e egfr
AR127896A1 (es) Proteínas que se unen a nkg2d, cd16 y 5t4
AR122120A1 (es) Moléculas de fijación para el tratamiento de cáncer
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
EA202192254A1 (ru) Fcmr-связывающие молекулы и их применение